Yibai Pharmaceutical announced that it has received an administrative penalty notice from the Guizhou Medical Products Administration, imposing a fine of 700,000 yuan for suspected failure to comply with drug manufacturing quality management standards. An investigation found multiple issues, including 27 batches of sucrose and one batch of vanillin excipient not being tested according to procedures upon incoming inspection, inconsistent disinfection time records for the purified water preparation system, and the absence of paper cleaning operation records for the pediatric cough syrup dispensing system. The company stated that this penalty is a follow-up administrative action to the previously disclosed suspension and rectification of pediatric cough syrup production in 2025. After rectification, production and sales of the product resumed in September 2025, and this administrative penalty does not involve any new violations.
Guizhou Yibai Pharmaceutical Co LtdFined 700,000 yuan for violating drug manufacturing quality standards, though no new violations beyond previously disclosed suspension.